Weaver syndrome, first described in 1974, is characterized by tall stature, a typical facial appearance and variable intellectual disability. In 2011, mutations in the histone methyltransferase, EZH2, were shown to cause Weaver syndrome. To date, we have identified 48 individuals with EZH2 mutations. The mutations were primarily missense mutations occurring throughout the gene, with some clustering in the SET domain (12/48). Truncating mutations were uncommon (4/48) and only identified in the final exon, after the SET domain. Through analyses of clinical data and facial photographs of EZH2 mutation-positive individuals, we have shown that the facial features can be subtle and the clinical diagnosis of Weaver syndrome is thus challenging, especially in older individuals. However, tall stature is very common, reported in >90% of affected individuals. Intellectual disability is also common, present in ~80%, but is highly variable and frequently mild. Additional clinical features which may help in stratifying individuals to EZH2 mutation testing include camptodactyly, soft, doughy skin, umbilical hernia and a low, hoarse cry. Considerable phenotypic overlap between Sotos and Weaver syndromes is also evident. The identification of an EZH2 mutation can therefore provide an objective means of confirming a subtle presentation of Weaver syndrome and/or distinguishing Weaver and Sotos syndromes. As mutation testing becomes increasingly accessible and larger numbers of EZH2 mutation-positive individuals are identified, knowledge of the clinical spectrum and prognostic implications of EZH2 mutations should improve.
In 1974, David Weaver and colleagues described two boys with accelerated osseous maturation, unusual facies and camptodactyly and proposed that this constellation of phenotypic features constituted a novel clinical entity (Weaver et al 1974) . Subsequent to this initial description over 50 individuals with similar and additional clinical features were reported and the condition became eponymously known as Weaver syndrome (MIM 277590, Ardinger et al 1986; Bansal et al 2009; Basel-Vanagaite 2010; Cole et al 1992; Coulter et al 2008; Crawford et al 2005; Derry et al 1999; Dumic et al 1993; Farrell et al 1985; Freeman et al 1999; Fryer et al 1997; Greenberg et al 1989; Huffman et al 2001; Iatrou et al 2008; Kelly et al 2000; Kondo et al 1990; Kondo et al 1991; Majewski et al 1981; Meinecke et al 1983; Mikalef et al 2010; Muhonen et al 1990; Ozkan et al 2000; Proud et al 1998; Ramos-Arroyo et al 1991; Roussounis et al 1983; Sarigul et al 1999; Scarano et al 1996; Thompson et al 1987; Tsukahara et al 1984) . However, because of the subtlety of the Weaver syndrome phenotype and the overlap with other overgrowth syndromes, particularly Sotos syndrome, the clinical diagnosis can be challenging, even for the experienced dysmorphologist. Thus the robustness of the many reported Weaver syndrome clinical associations is unclear.
In 2011 we and another, independent, group reported that constitutional EZH2 mutations cause Weaver syndrome (Gibson et al 2011; Tatton-Brown et al 2011) . EZH2 (Enhancer of Zeste homolog 2) is located at 7q36.1 and encodes a histone methyltransferase involved in chromatin modeling and transcriptional repression. In combination with EED (Embryonic Ectoderm Development protein, mouse, homolog of) and SUZ12 (Suppressor of Zeste 12, drosophila, homolog of), it forms the polycomb repressive complex 2 (PCR2) which catalyzes the methylation of lysine residue 27 of histone 3 (H3K27) resulting in chromatin compaction and repression of transcription (Cao et al 2002) . EZH2 activity is inhibited by AKT (v-akt murine thymoma viral oncogene homolog 1), a key component of the PI3K/mTOR growth regulatory pathway, through the phosphorylation of serine 21 which blocks binding of EZH2 to histone 3 (Cha et al 2005) .
Tatton-Brown et al 5 Somatic activating and inactivating mono-and biallelic EZH2 mutations have been identified in multiple hematological malignancies (Chase et al 2011) . A recurrent monoallelic activating Tyr646 mutation has been identified in lymphomas, particularly diffuse large cell B-cell type and follicular lymphomas (Morin et al 2010; Sneeringer et al 2010) . In contrast, inactivating mono-and biallelic missense and truncating mutations, throughout EZH2, are associated with poor prognosis myelodysplastic and myeloproliferative neoplasms (Ernst et al 2010) .
In our initial 2011 paper on EZH2 and Weaver syndrome we described 19 individuals with EZH2 mutations (Tatton-Brown et al 2011) . Subsequent to this study we have extended our molecular and clinical analyses to identify, in total, 48 individuals with EZH2 mutations from 39 unrelated families. Using data from these cases, we have defined the EZH2 mutational spectrum and provide the first detailed evaluation of the clinical features associated with EZH2-related Weaver syndrome.
Patients and Methods

Case Series
The research was approved by the London Multicentre Research Ethics Committee and consent was obtained from participating individuals and/or their parents. Individuals recruited to the Childhood Overgrowth Genetics (COG) study with variable overgrowth phenotypes were screened for mutations in EZH2. 48 individuals, 20 males and 28 females, with EZH2 mutations (termed EZH2 mutation-positive individuals) were identified. The patients had been recruited from Clinical Genetics centers worldwide and included 25 from the UK; 10 from the USA; three from France; two from the Netherlands; two from Portugal; two from the Reunion Islands and one from each of Austria, Belgium, the Republic of Ireland and Japan. Clinical information, in the form of a standardized overgrowth questionnaire (routinely sent to recruiting physicians) and an EZH2-specific supplementary questionnaire, was requested for all EZH2 mutation-positive individuals (see Supplementary Figure 1 ). Photographs were additionally Tatton-Brown et al 6 received for 43 of the EZH2 mutation-positive individuals. These were shown to a panel of five experienced dysmorphologists who assigned them to one of three phenotypic categories: 1) "typical Weaver syndrome"; 2) "possible Weaver syndrome" or 3) "not Weaver syndrome". If a patient was assigned to the latter category and an alternative diagnosis such as Sotos syndrome was suspected, this was noted. Where possible, a majority score was used.
However, if the results from the five panelists were divergent, an average (median) score was calculated and used. The patient's age when the photograph was taken was recorded as <1 years, 1-5 years, 5-10 years or >10 years.
Molecular Studies
Four individuals (cases 19, 34, 40 and 46, Supplementary Table 1 ) were identified to have EZH2 mutations through exome sequencing as previously described (Snape et al 2011; Tatton-Brown et al 2011) . We subsequently performed Sanger sequencing of the full coding sequence and intron-exon boundaries of EZH2 in 431 additional individuals from the COG study. We analyzed parental samples for the specific EZH2 mutation identified in the proband, if samples were available.
Statistical analyses
Independence of effects of phenotype group and age range was analyzed using a 4x3 contingency table, examining for deviation from the expected distribution (under the null hypothesis of independence of effects) using Pearson's chi-squared test (6df).
Results
EZH2 mutational spectrum
We identified 48 EZH2 mutations including 44 missense and four truncating variants ( Figure   1a ). Variants were considered to be pathogenic if they were de novo, familial and clearly segregating with the overgrowth phenotype or identical to a variant that had been classified as pathogenic in another individual. Thirty-eight variants fulfilled these criteria ( Supplementary   Table 1 ). DNA was not available from both parents of two individuals with truncating variants; two individuals in whom the same amino acid residue, Arg684 and Glu148, had been substituted by a different amino acid as a de novo event in at least one other individual; one individual with an in-frame duplication and four individuals with missense variants. An additional patient had inherited a His618Tyr missense mutation from his father who did not have a clear overgrowth phenotype ( Supplementary Table 1 ). However, none of these variants were identified in over 2000 in-house exomes from controls or breast cancer patients nor in over 6000 exomes in the Exome variant server (http://evs.gs.washington.edu/EVS/) and all the missense variants affected highly conserved residues ( Figure 1b ). Therefore, although we cannot be unequivocally certain of pathogenicity because the penetrance/expressivity of the mutations can be variable/mild, we considered it likely that these variants were causative of the overgrowth phenotype.
The 44 missense mutations were distributed throughout the gene with some clustering in the highly conserved SET domain (12/44, Figure 1a ). Two SET domain mutations, Arg684Cys and Ser652Cys, were seen recurrently: the Arg684Cys mutation in five unrelated individuals and the Ser652Cys mutation in two unrelated individuals. Only four truncating mutations were identified, all in the post-SET terminal exon, exon 20.
Clinical features associated with EZH2 mutations
The typical Weaver syndrome facial gestalt can be subtle and challenging to recognize Amongst the 43 EZH2 mutation-positive individuals in whom facial photographs were assessed and categorized, 20 were assigned to group 1 (classic Weaver syndrome), eleven to group 2 (possible Weaver syndrome) and 12 to group 3 (not typical for Weaver syndrome). In group 1, 10 individuals were at least 1 year and one individual was >10 years (with five and four individuals 1-5 years and 5-10 years respectively). In group 2, one individual was <1 year, Tatton-Brown et al 8 four were 1-5 years, two were 5-10 years and four were >10 years and in group 3 there were no individuals who were <1 year, three were 1-5 year, one was 5-10 year and eight were >10 years ( Figure 2 ). This distribution of ages and phenotypic group represented a significant excess of younger cases in group 1 and older cases in group 3 (χ 2 =19.6, P=0.003 [6df]). The EZH2-related growth profile Information regarding birth weight was available for 39 babies: 22 females and 17 males. Only 38% (15/39, including 11 females and four males) EZH2 mutation-positive babies had a birth weight greater than two standard deviations above the mean (+2 SDs) with a median birth weight of +1.3 SDs and a range of -1.6 SDs to +4.6 SDs. Birth length is likely to be a better correlate of an EZH2 mutation with EZH2 mutation-positive babies frequently described as long and skinny. Unfortunately, however, length is not always measured at birth and, even when it is, parental recall is not as accurate as for weight. However, of the 18 babies with EZH2 mutations and a birth length recorded, 12 had a length greater than two standard deviations above the mean with an overall range of -0.5 SDs to +4.9 SDs ( Supplementary   Table 1 ).
Information regarding subsequent growth (height and head circumference) was available for 45 EZH2 mutation-positive individuals of whom nine were adults (>18 years) and 36 were children (with ages between 0.4 and 16.6 years and a median age of 3.5 years). 35 of the children and six of the adults (in total 41/45 (91%)) had a height at least two standard deviations above the mean and in 14 children and two adults the height was at least +4 SDs (Figure 4a , Supplementary Table 1 ). Included amongst the four individuals whose height was less than +2 SDs, were three adults who were reported to be tall as young children: case 4 was overgrown until she developed a severe scoliosis at the age of 18 months for which she subsequently required spinal surgery as a teenager; the height of case 42 was 5.7 standard deviations above the mean until the age of three after which growth velocity decelerated for no apparent reason and case 3 was reported to be tall as a child but information from childhood was unfortunately not available. In contrast to height, head circumference measurements in 40 EZH2 mutation-positive children and adults ranged from -0.9 SDs to +5.5 SDs with a median value of +1.8 SDs (Figure 4b , Supplementary Table 1 ).
Most EZH2-mutation positive individuals have a mild intellectual disability
Amongst the 45 EZH2 mutation-positive individuals where information on intellect was provided, the majority had an intellectual disability (37/45, 82%) but this was most frequently mild (21/37, 57%). Twelve individuals had a moderate intellectual disability and only two had a severe disability. In addition, two individuals were said to have intellectual disability but the degree of impairment was not provided. Eight individuals were reported to have normal intelligence, two individuals were considered too young to be able to assess the degree of intellectual impairment and no information was available for one individual. Supplementary Table 1 ). It is noteworthy that eight of the 17 individuals with umbilical hernia required surgical repair. Although not specifically solicited on either the general or EZH2specific questionnaire, flexion of the proximal and hyperextension of the distal interphalangeal joints (analogous to a mild boutonniere deformity) was identified through clinical examination of five affected adults. This deformity was not associated with any detriment to function but may be a useful diagnostic clue in older EZH2 mutation-positive individuals.
Tumors occur, but not at high frequency, in EZH2 mutation-positive individuals
Tumors were reported in only two EZH2 mutation-positive individuals: case 45 with a Glu745Lys missense mutation and a lymphoma diagnosed at the age of 13 years and case 31 with an Ala682Thr mutation, who developed acute lymphoblastic leukemia and neuroblastoma both at 13 months ( Supplementary Table 1 ). Despite the association between somatic inactivating mutations and chronic hematological malignancies, none of the latter were reported amongst the 48 EZH2 mutation-positive individuals.
Imaging investigations in EZH2 mutation-positive Weaver syndrome
Osseous maturation was only assessed in 25 EZH2 mutation-positive individuals but was advanced in all. Of interest, a discrepancy between the carpal and phalangeal bone maturation, with greater maturation reported for the carpal bones, was recorded for three affected individuals. However, this may be an underestimate of the number of EZH2 mutationpositive individuals with a carpal/phalangeal bone age discrepancy as details additional to bone and chronological age were not requested on the clinical questionnaires.
Nine EZH2 mutation-positive individuals, in whom brain imaging had been undertaken, had abnormal studies including four with isolated ventriculomegaly; one individual with ventriculomegaly and periventricular leukomalacia and four individuals each with either periventricular leukomalacia; pachygyria and polymicrogyria; a small infracted area in the cerebellum or a persistent cavum septum pellucidum ( Supplementary Table 1 ).
Other clinical features
Other clinical features reported in more than one but less than 10 EZH2 mutation-positive individual are shown in Table 1 . Until greater numbers of EZH2 mutation-positive individuals are ascertained, it is not clear which of these features are true EZH2 associations and which are coincidental, particularly for features that are common in the general population.
Discussion
Through the identification of 48 EZH2 mutation-positive individuals we have demonstrated that missense mutations are the primary EZH2 mutational mechanism in Weaver syndrome, present in over 90% of affected individuals. To date, only four truncating mutations have been identified, all within the terminal exon, and therefore likely escape nonsense mediated RNA decay and result in a truncated protein that retains the SET domain. The predominance of missense mutations and the terminal location of the truncating mutations suggest that simple EZH2 haploinsufficiency is unlikely to be the cause of Weaver syndrome. This is corroborated by phenotypic data published for five cases with deletions encompassing EZH2 where tall stature or overgrowth is not reported although the authors have recently been informed of one case with tall stature and a 1.2Mb deletion encompassing EZH2 (http: //decipher.sanger.ac.uk/) . Functional studies to investigate the mechanism of pathogenesis would be of interest, particularly as the EZH2 mutational spectrum in Weaver syndrome differs from the somatic mutational profile in hematological malignancies.
The clinical features associated with EZH2 mutations are variable and rather non-specific, and clinical diagnosis is therefore challenging. Less than half (47%) of the EZH2 mutation-positive individuals were considered to have the classic Weaver syndrome facial gestalt. However, it is noteworthy that the distribution of ages in the group 1 compared with group 3 are very different with over-representation of individuals < 1 year of age in group 1 and individuals > 10 years of age in group 3. This age distribution suggests that the facial phenotype is more easily recognized in younger childhood, that there is greater familiarity with the Weaver syndrome facial gestalt in this age range, or both. The data also suggest that review of photographs at younger ages may be helpful if a diagnosis of Weaver syndrome is being considered in older children or adults. The presence of additional features may also be helpful. Tall stature, with a height at least two standard deviations above the mean, is the most consistent EZH2-related clinical feature, present in approximately 90% of affected individuals. Intellectual disability is also common, present in ~80%, but can be very mild. Unfortunately both features are nonspecific and generally common, which limits their utility as discriminating clinical features of Weaver syndrome.
More specific, but less frequent EZH2-related associations of Weaver syndrome, identified in 30-50% of affected individuals, include camptodactyly, hoarse, low cry and soft, doughy skin.
Many of these features are present in the neonatal period / early childhood and later resolve; they may be missed if a detailed neonatal / early childhood history is unavailable.
Five of the 48 individuals in our study were considered to have the facial features of Sotos syndrome, exemplifying the considerable clinical overlap between these two overgrowth conditions (table 2). The facial features associated with NSD1 mutations are more distinctive than those of EZH2, and increased head circumference is more characteristic of NSD1 mutations than EZH2 mutations. However, robust clinical differentiation between these two conditions is not possible and thus NSD1 mutation analysis should also be considered if EZH2 testing is negative, and vice versa. Multi-gene testing, for example by next-generation sequencing targeted gene or exome assays, will be the optimal analysis allowing both genes to be analyzed.
The identification of constitutional EZH2 mutations as a cause of Weaver syndrome has provided an objective means of diagnosing a frequently subtle condition, but there is still much to learn. The molecular mechanism by which EZH2 mutations result in Weaver syndrome is unknown and the relationship between the clinical manifestations of germline and somatic EZH2 mutations is intriguing. For example, three missense mutations Gly159Arg, Arg684Cys
and Tyr733*, have been reported somatically in myeloid malignancies and were identified constitutionally in eight unrelated individuals in the current series. None of these individuals has developed a malignancy although, in contrast to our series with constitutional mutations comprised predominantly of affected children, the majority of individuals with myeloid malignancies are typically >60 years. There are currently very little data about the phenotype of individuals with Weaver syndrome in late adulthood, but the available evidence suggests they may be at increased risk of hematological malignancies. Long-term follow-up studies should be able to address this in due course but until these data are available we would recommend clinical vigilance and investigation of any potential tumor related symptoms rather than a specific surveillance program. It would also be of interest to investigate if any of the individuals with hematological malignancies in whom somatic EZH2 mutations have been identified, in fact have constitutional mutations and undiagnosed Weaver syndrome. Given the mild and subtle phenotype of Weaver syndrome, this is plausible and readily evaluated through analyses of buccal DNA.
Although the current study has allowed characterization of the EZH2-mutation phenotype and is, to our knowledge, the world's largest cohort, it is a small series. With genetic analysis becoming ever-more accessible, the number of individuals identified with an EZH2 mutation is likely to increase rapidly. This will facilitate understanding of the phenotype at all ages, Tatton-Brown et al 14 genotype-phenotype associations and more accurate prognostic information. In turn this will allow optimal management for individuals with Weaver syndrome.
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